GNI Group Ltd. (JP:2160)
:2160
2160 Stock Chart & Stats
¥3110.00
¥50.00(1.64%)
At close: 4:00 PM EST
¥3110.00
¥50.00(1.64%)
Day’s Range― - ―
52-Week Range¥1,560.00 - ¥4,410.00
Previous CloseN/A
Volume492.20K
Average Volume (3M)969.16K
Market Cap
¥180.18B
Enterprise Value¥158.56B
Total Cash (Recent Filing)¥21.10B
Total Debt (Recent Filing)¥5.37B
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 15, 2026EPS Estimate
-2.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-74.44
Shares Outstanding55,698,696
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,777.61Price Target Upside21.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.4
Revenue Forecast (FY)¥33.25B
Bulls Say, Bears Say
Bulls Say
Balance Sheet ResilienceVery low debt-to-equity and material equity growth provide durable financial flexibility. This conservatism reduces refinancing and interest risk, supports continued R&D and commercialization spend during cash burn periods, and improves survival odds through execution cycles.
Sustained Revenue Growth TrendLong-run revenue expansion demonstrates recurring commercial traction and market demand for products. Even with volatility, the underlying revenue base and recent rebound support structural revenue opportunities from existing products and licensing streams over the next several quarters.
Robust Pipeline And Diversified Commercial ModelA focused pipeline in high-unmet-need therapeutic areas plus licensing and partnership channels diversifies future revenue pathways. This business model supports sustained product launches, milestone income and royalties, strengthening medium-term growth prospects beyond single-product risk.
Bears Say
Negative Operating And Free Cash FlowConsecutive years of negative OCF and FCF indicate the business is not self-funding current operations. Persistent cash burn raises the likelihood of near-term external financing or dilution, constrains discretionary R&D/commercial investment, and elevates execution and funding risk.
2025 Profitability DeteriorationA material swing to net losses weakens earnings quality and reduces retained earnings available for reinvestment. If losses persist, management may need to re-prioritize programs, cut costs, or seek external capital, which can slow product development and commercialization momentum.
Volatile Growth And Margin PressureHigh gross margins but collapsing operating/net margins signal rising operating costs or one-off charges. This margin instability undermines forecasting, complicates partner negotiations and capital allocation, and increases the difficulty of delivering consistent profitability in the medium term.
GNI Group News
2160 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was ¥1560.00 and its highest was ¥4410.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is ¥180.18B.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is May 15, 2026 which is in 36 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -¥74.44 earnings per share for the quarter, missing the consensus estimate of ¥224.642 by -¥299.082.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -2.74.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,698,696 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -¥74.44 in its last earnings report, missing expectations of ¥224.642. Following the earnings report the stock price went down -3.49%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in JP:2160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
2160 Stock 12 Month Forecast
Average Price Target
¥3,777.61
▲(21.47% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---